Talking multiomics data and how it can take pharmacogenomics to the next level such as in predicting patient response.
Talking multiomics data and how it can take pharmacogenomics to the next level such as in predicting patient response.
Featuring Sapient’s platform as an omics technology advancing the discovery & implementation of dynamic biomarkers.
How multi-omics biomarker strategies are helping to realize the incredible therapeutic potential in these pipelines today.
Dr. Usuka will lead global business strategy for commercial collaborations, strategic partnerships & client service innovations.
Using metabolite biomarkers to speed GLP-1 agonist time-to-market & drive competitive advantages via novel insights.
Explore how our /Deep/ Cell Surface Proteomics method is optimized to accelerate development of T cell engagers.
See how our method is optimized to measure cancer cell surface receptors at unprecedented depth and scale.
PharmaShots profiles Sapient’s high throughput proteomics and how our services fulfill market gaps for drug development.
See how our method is optimized to evaluate degrader specificity & to screen thousands of degrader molecules for target efficiency.
Discussing how next-gen multiomics is enabling drug development transformation in the post-COVID era.
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
